Cellworks Singula™ Therapy Response Index (TRI) Identifies Superior OS Outcomes for NSCLC Patients: myCare-203A
Superior Overall Survival(OS), progression-free survival(PFS), and clinical response(CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula™ : myCare-022-05
to personalized therapy predictions
in 30 seconds
Predicting response to treatment with Carboplatin + Pembrolizumab in a NSCLC patient
Predicting response to treatment with Afatinib in a NSCLC patient
Predicts personalized response to Standard Care therapies for front-line patients
Predicts and ranks personalized response to combinations of FDA-approved drugs including off-label and non-oncology drugs for refractory patients
Observational Clinical Trial for Assessment of Clinical Utility and Usability of Cellworks Reports
Pan-cancer (150+ cancer indications)
Turn a patient’s NGS report into personalized therapy predictions at no cost and provide usability feedback on Cellworks reports through a survey. No requirement to follow therapy predictions.
Avera and University of Tennessee
Clinical Trial to Predict Optimal Personalized Treatment for Veterans with NSCLC
A prospective clinical trial to determine if Cellworks personalized therapy biosimulation more accurately predicts patient response to NSCLC Standard Care therapies than physician prescribed treatment.
Veterans Administration and University of Nebraska